ArticleSchizophrenia bulletin2018
Study of Novel Autoantibodies in Schizophrenia.
Article in Schizophrenia bulletin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives.Frontiers in psychiatry · 2022Pooled it
- Association Between Peptide Antigen-Related Antibody Levels and the Short- and Long-Term Efficacy of Antipsychotic Treatment in Drug-Naïve First-Episode Schizophrenia Patients.Schizophrenia bulletin · 2026Article
- Molecular Mimicry BetweenInternational journal of molecular sciences · 2025Article
- Autoantibodies and Inflammation in Schizophrenia.Psychiatry and clinical neurosciences · 2025Review
- Psychiatric Symptoms in Wilson's Disease-Consequence ofInternational journal of molecular sciences · 2024Review
- Signals of selection and ancestry in independently feral Gallus gallus populations.Molecular ecology · 2024Article
- DNA Hyper-methylation Associated With Schizophrenia May Lead to Increased Levels of Autoantibodies.Schizophrenia bulletin open · 2024Article
- An examination of plasma autoantibodies against voltage gated calcium channels in schizophrenia.Brain, behavior, & immunity - health · 2023Article
- Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia.Life (Basel, Switzerland) · 2022Article
- Skewing of the antibody repertoire in cerebrospinal fluid B cells from healthy controls and patients with schizophrenia.Behavioural brain research · 2022Article
- The SFT2D2 gene is associated with the autoimmune pathology of schizophrenia in a Chinese population.Frontiers in neurology · 2022Article
- Decreased BOLD signals elicited by 40-Hz auditory stimulation of the right primary auditory cortex in bipolar disorder: An fMRI study.Frontiers in psychiatry · 2022Article
- Autoantibody profiles associated with clinical features in psychotic disorders.Translational psychiatry · 2021Article
- MAD1L1 and TSNARE gene polymorphisms are associated with schizophrenia susceptibility in the Han Chinese population.BMC medical genomics · 2021Article
- Impaired blood-brain barrier in the microbiota-gut-brain axis: Potential role of bipolar susceptibility gene TRANK1.Journal of cellular and molecular medicine · 2021Review
- Molecular signature of extracellular matrix pathology in schizophrenia.The European journal of neuroscience · 2021Article
- Exploring autoantibody signatures in brain tissue from patients with severe mental illness.Translational psychiatry · 2020Article
- Anti-TSNARE1 IgG plasma levels differ by sex in patients with schizophrenia in a Chinese population.FEBS open bio · 2019Article
- Further Study of Circulating Antibodies to P16, CD25 and FOXP3 in Hepatocellular Carcinoma.OncoTargets and therapy · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent genome-wide association (GWA) study confirmed 108 genetic loci that were strongly associated with schizophrenia. Fifteen schizophrenia-associated genes were selected for this study based on a number of selection criteria including their high expression in both brain tissues and B-lymphocyte cells. We aimed to investigate whether individuals with schizophrenia showed different levels of plasma IgG antibodies against protein-derived fragments encoded by these 15 genes. A total of 356 plasma samples were used to analyze circulating IgG antibodies against 18 target peptide antigens using an in-house enzyme-linked immunosorbent assay. Of 18 antigens tested, 6 (derived from DPYD, MAD1L1, ZNF804A, DRD2, TRANK1, and MMP16, respectively) showed increased IgG levels and 3 (derived from TSNARE1, TCF4, and VRK2, respectively) showed decreased IgG levels in patients with schizophrenia compared with control subjects. Receiver operating characteristic (ROC) curve analysis revealed that the anti-TRANK1 IgG assay had the area under the ROC curve of 0.68 (95% CI = 0.62-0.73), with the highest sensitivity of 20.7% against specificity of 95.2% among all 18 tests. There was no difference in positivity of anti-double strand DNA IgG between the patient group and the control group and no correlation between total IgG levels and each individual IgG level tested. Although risperidone treatment showed confounding effects on overall IgG levels in the circulation (combined P = .005), anti-TRANK1 IgG levels did not appear to be significantly affected (t = 1.358, P = .176). In conclusion, this study suggests that circulating anti-TRANK1 IgG is likely to serve as a biomarker for identification of a subgroup of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.